Hormonal manipulation of benign prostatic hyperplasia

Ferenc G. Rick, Seyed H. Saadat, Luca Szalontay, Norman L Block, Amir Kazzazi, Bob Djavan, Andrew V Schally

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH). The latest treatment findings with 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride, refined indications, efficacy, and safety are discussed and compared. We also discuss potential new 5-ARIs and other hormonal treatments. RECENT FINDINGS: Finasteride and dutasteride have equal efficacy and safety for the treatment and prevention of progression of BPH. 5-ARIs are especially recommended for prostates greater than 40 ml and PSA greater than 1.5 ng/ml. Combination therapy is the treatment of choice in these patients, but with prostate volume greater than 58 ml or International Prostate Symptom Score of at least 20, combinations have no advantage over 5-ARI monotherapy. Updates on the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed. Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink experimentally enlarged prostates alone or in combination with LHRH antagonists. SUMMARY: New 5-ARIs seem to be the promising agents that need further study. Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate volume. Recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors. The adverse effects of 5ARIs encourage alternative therapy.

Original languageEnglish
Pages (from-to)17-24
Number of pages8
JournalCurrent Opinion in Urology
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

5-alpha Reductase Inhibitors
Hormone Antagonists
Prostatic Hyperplasia
Prostate
Gonadotropin-Releasing Hormone
Growth Hormone-Releasing Hormone
Finasteride
Therapeutics
Safety
Complementary Therapies

Keywords

  • 5-alpha reductase inhibitor
  • benign prostatic hyperplasia
  • gonadotropin-releasing hormone
  • growth hormone-releasing hormone
  • lower urinary tract symptoms
  • luteinizing hormone-releasing hormone

ASJC Scopus subject areas

  • Urology

Cite this

Rick, F. G., Saadat, S. H., Szalontay, L., Block, N. L., Kazzazi, A., Djavan, B., & Schally, A. V. (2013). Hormonal manipulation of benign prostatic hyperplasia. Current Opinion in Urology, 23(1), 17-24. https://doi.org/10.1097/MOU.0b013e32835abd18

Hormonal manipulation of benign prostatic hyperplasia. / Rick, Ferenc G.; Saadat, Seyed H.; Szalontay, Luca; Block, Norman L; Kazzazi, Amir; Djavan, Bob; Schally, Andrew V.

In: Current Opinion in Urology, Vol. 23, No. 1, 01.01.2013, p. 17-24.

Research output: Contribution to journalArticle

Rick, FG, Saadat, SH, Szalontay, L, Block, NL, Kazzazi, A, Djavan, B & Schally, AV 2013, 'Hormonal manipulation of benign prostatic hyperplasia', Current Opinion in Urology, vol. 23, no. 1, pp. 17-24. https://doi.org/10.1097/MOU.0b013e32835abd18
Rick FG, Saadat SH, Szalontay L, Block NL, Kazzazi A, Djavan B et al. Hormonal manipulation of benign prostatic hyperplasia. Current Opinion in Urology. 2013 Jan 1;23(1):17-24. https://doi.org/10.1097/MOU.0b013e32835abd18
Rick, Ferenc G. ; Saadat, Seyed H. ; Szalontay, Luca ; Block, Norman L ; Kazzazi, Amir ; Djavan, Bob ; Schally, Andrew V. / Hormonal manipulation of benign prostatic hyperplasia. In: Current Opinion in Urology. 2013 ; Vol. 23, No. 1. pp. 17-24.
@article{016813618fc74126ace2383b9112029d,
title = "Hormonal manipulation of benign prostatic hyperplasia",
abstract = "PURPOSE OF REVIEW: We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH). The latest treatment findings with 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride, refined indications, efficacy, and safety are discussed and compared. We also discuss potential new 5-ARIs and other hormonal treatments. RECENT FINDINGS: Finasteride and dutasteride have equal efficacy and safety for the treatment and prevention of progression of BPH. 5-ARIs are especially recommended for prostates greater than 40{\^a}€Šml and PSA greater than 1.5{\^a}€Šng/ml. Combination therapy is the treatment of choice in these patients, but with prostate volume greater than 58{\^a}€Šml or International Prostate Symptom Score of at least 20, combinations have no advantage over 5-ARI monotherapy. Updates on the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed. Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink experimentally enlarged prostates alone or in combination with LHRH antagonists. SUMMARY: New 5-ARIs seem to be the promising agents that need further study. Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate volume. Recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors. The adverse effects of 5ARIs encourage alternative therapy.",
keywords = "5-alpha reductase inhibitor, benign prostatic hyperplasia, gonadotropin-releasing hormone, growth hormone-releasing hormone, lower urinary tract symptoms, luteinizing hormone-releasing hormone",
author = "Rick, {Ferenc G.} and Saadat, {Seyed H.} and Luca Szalontay and Block, {Norman L} and Amir Kazzazi and Bob Djavan and Schally, {Andrew V}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/MOU.0b013e32835abd18",
language = "English",
volume = "23",
pages = "17--24",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hormonal manipulation of benign prostatic hyperplasia

AU - Rick, Ferenc G.

AU - Saadat, Seyed H.

AU - Szalontay, Luca

AU - Block, Norman L

AU - Kazzazi, Amir

AU - Djavan, Bob

AU - Schally, Andrew V

PY - 2013/1/1

Y1 - 2013/1/1

N2 - PURPOSE OF REVIEW: We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH). The latest treatment findings with 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride, refined indications, efficacy, and safety are discussed and compared. We also discuss potential new 5-ARIs and other hormonal treatments. RECENT FINDINGS: Finasteride and dutasteride have equal efficacy and safety for the treatment and prevention of progression of BPH. 5-ARIs are especially recommended for prostates greater than 40 ml and PSA greater than 1.5 ng/ml. Combination therapy is the treatment of choice in these patients, but with prostate volume greater than 58 ml or International Prostate Symptom Score of at least 20, combinations have no advantage over 5-ARI monotherapy. Updates on the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed. Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink experimentally enlarged prostates alone or in combination with LHRH antagonists. SUMMARY: New 5-ARIs seem to be the promising agents that need further study. Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate volume. Recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors. The adverse effects of 5ARIs encourage alternative therapy.

AB - PURPOSE OF REVIEW: We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH). The latest treatment findings with 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride, refined indications, efficacy, and safety are discussed and compared. We also discuss potential new 5-ARIs and other hormonal treatments. RECENT FINDINGS: Finasteride and dutasteride have equal efficacy and safety for the treatment and prevention of progression of BPH. 5-ARIs are especially recommended for prostates greater than 40 ml and PSA greater than 1.5 ng/ml. Combination therapy is the treatment of choice in these patients, but with prostate volume greater than 58 ml or International Prostate Symptom Score of at least 20, combinations have no advantage over 5-ARI monotherapy. Updates on the recent developments on BPH therapy with luteinizing hormone-releasing hormone (LHRH) antagonist are also reviewed and analyzed. Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effectively shrink experimentally enlarged prostates alone or in combination with LHRH antagonists. SUMMARY: New 5-ARIs seem to be the promising agents that need further study. Preclinical studies revealed that GHRH and LHRH antagonists both can cause a reduction in prostate volume. Recent data indicate that prostate shrinkage is induced by the direct inhibitory action of GHRH and of LHRH antagonists exerted through prostatic receptors. The adverse effects of 5ARIs encourage alternative therapy.

KW - 5-alpha reductase inhibitor

KW - benign prostatic hyperplasia

KW - gonadotropin-releasing hormone

KW - growth hormone-releasing hormone

KW - lower urinary tract symptoms

KW - luteinizing hormone-releasing hormone

UR - http://www.scopus.com/inward/record.url?scp=84871198115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871198115&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e32835abd18

DO - 10.1097/MOU.0b013e32835abd18

M3 - Article

C2 - 23202285

AN - SCOPUS:84871198115

VL - 23

SP - 17

EP - 24

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 1

ER -